Pharmaceutical Aspects of Pichia pastoris: Optimizing Recombinant Protein Expression for Drug Discovery and Development - 17/11/26
The advantages of Pichia pastoris in pharmaceutical applications [The figure is generated via a computational application called Napkin]
Highlights |
• | Recently, researchers have observed multiple unique properties in Pichia pastoris, making it ideal for manufacturing pharmaceutical products such as enzymes, vaccines, and peptides. |
• | It exhibits rapid growth, is cost-effective to cultivate, and survives high-stress conditions; these attributes have made it a priority for researchers and pharmaceutical companies for potential applications in pharmaceutical manufacturing and product development. Since 2009, it has been used to produce pharmaceutical products and has obtained FDA approval. |
• | The FDA has approved several drugs and healthcare products derived from Pichia pastoris, including Kalbitor®, Jetrea®, Eptinezumab-jjmr, and human insulin. Although Pichia pastoris is considered safe, many disadvantages and safety concerns persist in its use for healthcare product development. |
• | Nonetheless, due to advantages such as protein modification and higher expression levels, researchers continue to address disadvantages, including high methanol induction, glycosylation-related complications, and codon optimisation. |
• | Recent advances include effective genetic methods, such as CRISPR-Cas9, for precise genome modification in P. pastoris. It also highlights several research gaps in the application of Pichia pastoris in the pharmaceutical industry and proposes suggestions for future research. |
Abstract |
Recently, researchers have observed multiple unique properties in Pichia pastoris, making it ideal for manufacturing pharmaceutical products such as enzymes, vaccines, and peptides. It exhibits rapid growth, is cost-effective to cultivate, and survives high-stress conditions; these attributes have made it a priority for researchers and pharmaceutical companies for potential applications in pharmaceutical manufacturing and product development. Since 2009, it has been used to produce pharmaceutical products and has obtained FDA approval. The FDA has approved several drugs and healthcare products derived from Pichia pastoris, including Kalbitor®, Jetrea®, Eptinezumab-jjmr, and human insulin. Although Pichia pastoris is considered safe, many disadvantages and safety concerns persist in its use for healthcare product development. Nonetheless, due to advantages such as protein modification and higher expression levels, researchers continue to address disadvantages, including high methanol induction, glycosylation-related complications, and codon optimization. Recent advances include effective genetic methods, such as CRISPR-Cas9, for precise genome modification in P. pastoris. It also highlights several research gaps in the application of Pichia pastoris in the pharmaceutical industry and proposes suggestions for future research.
Le texte complet de cet article est disponible en PDF.Résumé |
Récemment, des chercheurs ont observé de multiples propriétés uniques chez Pichia pastoris, ce qui en fait une plante idéale pour la fabrication de produits pharmaceutiques tels que des enzymes, des vaccins et des peptides. Sa croissance rapide, son faible coût de culture et sa capacité à survivre dans des conditions de stress élevé en ont fait une cible prioritaire pour les chercheurs et les entreprises pharmaceutiques, notamment pour des applications potentielles dans la fabrication et le développement de produits pharmaceutiques. Depuis 2009, elle est utilisée pour produire des médicaments et a obtenu l'approbation de la FDA. La FDA a approuvé plusieurs médicaments et produits de santé dérivés de Pichia pastoris, dont Kalbitor®, Jetrea®, Eptinezumab-jjmr et l'insuline humaine. Bien que Pichia pastoris soit considérée comme sûre, son utilisation pour le développement de produits de santé soulève encore de nombreux inconvénients et préoccupations en matière de sécurité. Néanmoins, grâce à des avantages tels que la modification des protéines et des niveaux d'expression plus élevés, les chercheurs continuent de s'attaquer aux inconvénients, notamment l'induction importante par le méthanol, les complications liées à la glycosylation et l'optimisation des codons. Parmi les avancées récentes, on peut citer des méthodes génétiques efficaces, telles que CRISPR-Cas9, pour la modification précise du génome de P. pastoris. Elle met également en lumière plusieurs lacunes de la recherche concernant l'application de Pichia pastoris dans l'industrie pharmaceutique et propose des pistes pour de futures recherches.
Le texte complet de cet article est disponible en PDF.Abbreviations : FDA, HBV, DNA, HPV, GRAS, CHO, CEA, hGH, EPO, AOXI, GAP, FLD, ORF, HCDF, HEV, VPL, WHO, EMA, HIV, ART, AID, ERT, ML, AI
Keywords : eukaryotic cells, pharmaceutical products, yeast, protein, glucose, xylose, methanol, promoter, gene, vaccine
Mots clés : cellules eucaryotes, produits pharmaceutiques, levure, protéines, glucose, xylose, méthanol, promoteur, gène, vaccin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?

